Clinical Trial Update: Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating nivolumab for recurrent IDH-mutated high-grade gliomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• High-grade Glioma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: High Grade Glioma, Brain Cancer | Phase 2 | Status: COMPLETED